利福平、利福喷汀和KRM-1648对一组具有已知rpoB基因突变的耐利福平结核分枝杆菌分离株的抗分枝杆菌活性比较。
Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
作者信息
Moghazeh S L, Pan X, Arain T, Stover C K, Musser J M, Kreiswirth B N
机构信息
Tuberculosis Center, Public Health Research Institute, New York, New York 10016, USA.
出版信息
Antimicrob Agents Chemother. 1996 Nov;40(11):2655-7. doi: 10.1128/AAC.40.11.2655.
Abstract
A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase beta-subunit (rpoB) gene mutations was tested against the antimycobacterial agents rifampin, rifapentine, and KRM-1648 to correlate levels of resistance with specific rpoB genotypes. The results indicate that KRM-1648 is more active in vitro than rifampin and rifapentine, and its ability to overcome rifampin resistance in strains with four different genetic alterations may prove to be useful in understanding structure-function relationships.
摘要
收集了24株具有特征性RNA聚合酶β亚基（rpoB）基因突变的耐利福平结核分枝杆菌临床分离株，对其进行抗分枝杆菌药物利福平、利福喷汀和KRM-1648的测试，以将耐药水平与特定的rpoB基因型相关联。结果表明，KRM-1648在体外比利福平和利福喷汀更具活性，其克服具有四种不同基因改变菌株中利福平耐药性的能力可能有助于理解结构-功能关系。
相似文献
1
Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.利福平、利福喷汀和KRM-1648对一组具有已知rpoB基因突变的耐利福平结核分枝杆菌分离株的抗分枝杆菌活性比较。
Antimicrob Agents Chemother. 1996 Nov;40(11):2655-7. doi: 10.1128/AAC.40.11.2655.
2
Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.利福平、利福布汀和KRM-1648的抗分枝杆菌活性与结核分枝杆菌rpoB基因突变之间的关系。
J Antimicrob Chemother. 1998 Nov;42(5):621-8. doi: 10.1093/jac/42.5.621.
3
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.rpoB基因突变对结核分枝杆菌中利福霉素交叉耐药性产生的作用。
Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. doi: 10.1128/AAC.42.7.1853.
4
Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis.利福平与KRM-1648之间的交叉耐药性与结核分枝杆菌中的特定rpoB等位基因相关。
Int J Tuberc Lung Dis. 2002 Feb;6(2):166-70.
5
Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus.rpoB基因突变对利福平及KRM-1648抗金黄色葡萄球菌抗菌活性的差异影响。
J Antimicrob Chemother. 2001 Feb;47(2):153-6. doi: 10.1093/jac/47.2.153.
6
Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates.通过异源双链分析快速检测结核分枝杆菌分离株中的利福平耐药性，并确定耐利福平分离株中的利福霉素交叉耐药性。
J Clin Microbiol. 2003 Feb;41(2):816-8. doi: 10.1128/JCM.41.2.816-818.2003.
7
[In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].[利福平与利福喷汀对结核分枝杆菌交叉耐药性的体外研究]
Zhonghua Jie He He Hu Xi Za Zhi. 2005 Mar;28(3):192-4.
8
Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai.科威特和迪拜耐利福平临床结核分枝杆菌分离株中rpoB基因突变的特征分析
Diagn Microbiol Infect Dis. 2002 Nov;44(3):245-52. doi: 10.1016/s0732-8893(02)00457-1.
9
Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?利福喷汀早期杀菌活性的研究能否告诉我们如何预防获得性利福霉素耐药性复发？
Am J Respir Crit Care Med. 2005 Jul 1;172(1):4-5. doi: 10.1164/rccm.2504002.
10
In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.苯并恶嗪诺利福平霉素KRM-1648对结核分枝杆菌的体外和体内活性
Antimicrob Agents Chemother. 1995 Oct;39(10):2295-303. doi: 10.1128/AAC.39.10.2295.
引用本文的文献
1
An Overview of Various Rifampicin Analogs against and their Drug Interactions.各种利福平类似物对抗 和它们的药物相互作用概述。
Med Chem. 2024;20(3):268-292. doi: 10.2174/0115734064260853230926080134.
2
Heterologous production of the D-cycloserine intermediate O-acetyl-L-serine in a human type II pulmonary cell model.在人Ⅱ型肺细胞模型中 D-环丝氨酸中间产物 O-乙酰-L-丝氨酸的异源生产。
Sci Rep. 2023 May 26;13(1):8551. doi: 10.1038/s41598-023-35632-4.
3
Establishment and evaluation of an overlap extension polymerase chain reaction technique for rapid and efficient detection of drug-resistance in Mycobacterium tuberculosis.建立和评估重叠延伸聚合酶链反应技术，用于快速有效地检测结核分枝杆菌的耐药性。
Infect Dis Poverty. 2022 Mar 24;11(1):31. doi: 10.1186/s40249-022-00953-5.
4
A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens.一种半合成康力霉素对高负荷耐利福平病原体显示出体内疗效。
ACS Infect Dis. 2020 Sep 11;6(9):2431-2440. doi: 10.1021/acsinfecdis.0c00223. Epub 2020 Aug 25.
5
Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.利福平及利福霉素类似物对 RNA 聚合酶的抑制作用。
EcoSal Plus. 2020 Apr;9(1). doi: 10.1128/ecosalplus.ESP-0017-2019.
6
Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.新型生物安全滤纸条试剂盒的开发和评估，用于直接检测结核分枝杆菌及其相关耐药性的痰显微镜检查和运输。
PLoS One. 2019 Aug 13;14(8):e0220967. doi: 10.1371/journal.pone.0220967. eCollection 2019.
7
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.利福布汀治疗耐利福平肺结核患者的潜在用途。
J Antimicrob Chemother. 2018 Oct 1;73(10):2667-2674. doi: 10.1093/jac/dky248.
8
Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge.基于微阵列的快速检测结核分枝杆菌利福平、异烟肼和氟喹诺酮耐药性的单一试剂盒。
J Clin Microbiol. 2018 Jan 24;56(2). doi: 10.1128/JCM.01249-17. Print 2018 Feb.
9
Rifabutin Resistance Associated with Double Mutations in Gene in Isolates.利福布汀耐药与分离株中基因的双重突变相关。
Front Microbiol. 2017 Sep 14;8:1768. doi: 10.3389/fmicb.2017.01768. eCollection 2017.
10
Cell-Based High-Throughput Screening Identifies Rifapentine as an Inhibitor of Amyloid and Biofilm Formation in Escherichia coli.基于细胞的高通量筛选确定利福喷丁是大肠杆菌中淀粉样蛋白和生物膜形成的抑制剂。
ACS Infect Dis. 2015 Oct 9;1(10):460-8. doi: 10.1021/acsinfecdis.5b00055. Epub 2015 Aug 11.
本文引用的文献
1
Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan.日本分离的结核分枝杆菌菌株的利福平最低抑菌浓度（MIC）与rpoB基因突变之间的关系。
Antimicrob Agents Chemother. 1996 Apr;40(4):1053-6. doi: 10.1128/AAC.40.4.1053.
2
In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.新型利福霉素衍生物KRM-1648对结核分枝杆菌的体外杀菌及体内治疗活性
Antimicrob Agents Chemother. 1996 Feb;40(2):426-8. doi: 10.1128/AAC.40.2.426.
3
Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.KRM-1648与异烟肼联合使用对小鼠模型中结核分枝杆菌的活性。
Antimicrob Agents Chemother. 1996 Feb;40(2):298-301. doi: 10.1128/AAC.40.2.298.
4
Antimicrobial agent resistance in mycobacteria: molecular genetic insights.分枝杆菌中的抗菌药物耐药性：分子遗传学见解
Clin Microbiol Rev. 1995 Oct;8(4):496-514. doi: 10.1128/CMR.8.4.496.
5
Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis.简短报告：接受利福布汀预防治疗的患者发生耐利福平结核病
N Engl J Med. 1996 Jun 13;334(24):1573-6. doi: 10.1056/NEJM199606133342404.
6
Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS.艾滋病患者中耐单利福平结核分枝杆菌的独立起源
Am J Respir Crit Care Med. 1996 Feb;153(2):837-40. doi: 10.1164/ajrccm.153.2.8564140.
7
Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives.3'-羟基-5'-氨基苯并恶嗪利福霉素衍生物的合成及生物活性
Chem Pharm Bull (Tokyo). 1993 Jan;41(1):148-55. doi: 10.1248/cpb.41.148.
8
Tuberculosis symposium: emerging problems and promise.结核病研讨会：新出现的问题与前景
J Infect Dis. 1993 Sep;168(3):537-51. doi: 10.1093/infdis/168.3.537.
9
Evolution of drug-resistant tuberculosis: a tale of two species.耐多药结核病的演变：两个物种的故事。
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2428-9. doi: 10.1073/pnas.91.7.2428.
10
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.结核分枝杆菌中利福平耐药性突变的检测
Lancet. 1993 Mar 13;341(8846):647-50. doi: 10.1016/0140-6736(93)90417-f.
Zotero 插件